At Iroko, our commitment to improving the lives of patients is guided by executives with years of collective experience at the world’s leading pharmaceutical companies. Founded by professionals with proven skills and expertise in drug development and commercialization, our vision is backed by leadership focused on the future of pain management.

Board of Directors

Our directors share in the commitment to helping reshape pain management. With backgrounds in pharmaceuticals, academia, finance, and law, they offer the skill, experience, and industry knowledge to build a better future for Iroko, as well as for those who may benefit from our innovative products.

Osagie Imasogie

Founder, Iroko Pharmaceuticals, Inc.

Mr. Imasogie founded Iroko Pharmaceuticals in March 2007 and is Chairman of the Board. He is also Chairman of the Board of Directors of iCeutica, Inc. and Churchill Pharma. Mr. Imasogie is the co-founder and Senior Managing Partner of Phoenix IP Ventures.

Prior to co-founding Phoenix IP Ventures, Mr. Imasogie conceptualized and established GlaxoSmithKline Ventures and was its founding Vice President. In that position, he concluded over 30 transactions in which various GSK research and development assets were out-licensed to a number of companies and/or were the basis of starting new companies. Before GlaxoSmithKline Ventures, he was a Vice President for Product Development Strategy at SmithKline Beecham. Previously, he had been the Founding Senior Vice President for Business Development and General Counsel at Endo Pharmaceuticals Inc. and had served as a DuPont Merck Vice President for International Sales and Marketing and General Counsel to DuPont Merck’s International, Manufacturing, and Generic Drug divisions.

Earlier in his career, Mr. Imasogie had been a Price Waterhouse Corporate Finance Partner and a practicing attorney with a leading US law firm in the fields of corporate, corporate finance, taxation, and intellectual property law. Mr. Imasogie also co-founded Trigenesis Therapeutics Inc., a biopharmaceutical company focused on developing pharmaceutical products for the dermatological market, which was sold to a publicly traded pharmaceutical company. He also was the founder and former Chairman, President, and CEO of Ception Therapeutics, Inc.

Mr. Imasogie is a member of the Board of Overseers of the University of Pennsylvania Law School and the Board of Trustees of the University of Pennsylvania. He holds post-graduate degrees from the London School of Economics and the University of Pennsylvania Law School. Mr. Imasogie is a member of the New York State Bar and has been the I. Grant Irey Adjunct Professor at the University of Pennsylvania Law School, where he continues to teach a seminar on “Intellectual Property and National Economic Value Creation.” He is also a member of the Board of Commissioners of the Delaware River Port Authority.

Member of the Board

Louis J. Vollmer joined Iroko Pharmaceuticals as President in March 2015 having already joined Iroko’s Board of Directors in March 2013. In July 2016, he became President and Chief Executive Officer of Iroko Pharmaceuticals.

Mr. Vollmer spent the first 19 years of his career at DuPont Merck, beginning as a sales representative and eventually becoming the Vice President of Sales & Marketing for DuPont Multi‐Source Products with responsibility for more than 12 branded products. A co‐founder of the DuPont Pharmaceutical generics business, he was one of the partners responsible for the management buyout of that and other related businesses, which eventually became Endo Pharmaceuticals, Inc. At Endo, Mr. Vollmer was Executive Vice President of Sales & Marketing. In that role, he provided leadership in developing and implementing the strategies required to market Endo’s re‐protected and re‐positioned multi‐source and generic products into the marketplace. These efforts included marketing a re‐positioned Percocet® that offered more convenient doses for patients than the available generic combination oxycodone/acetaminophen products, launching a re‐protected generic hydrocodone as the branded product Zydone® and launching a re‐protected generic lidocaine as the branded product Lidoderm®. Lidoderm® eventually had annual sales of over $1BB and propelled Endo’s growth to become a multi‐billion dollar company.

Mr. Vollmer earned a Bachelor of Arts degree in biology and chemistry from the University of Delaware. Among the many awards he has received is membership in the DuPont Marketing Research Hall of Fame.

Percocet®, Zydone®, and Lidoderm® are registered trademarks of Endo Pharmaceuticals.

Member of the Board

Jeremy P. A. Fletcher joined the Iroko Pharmaceuticals Board of Directors in August 2010. He is a managing partner of Kew Capital, which he co-founded in 2008. He is also a member of the Board of Directors of iCeutica.

Previously, Mr. Fletcher was a Managing Director at Credit Suisse Securities (Europe) for 13 years, where he headed the bank’s global corporate advisory business focusing on the metals and mining industry. Before switching to investment banking in 2001, Mr. Fletcher was Credit Suisse’s European Steel Analyst and chair of the Credit Suisse global steel research team. He was ranked #1 in his sector in all major European and global polls, including Extel, Reuters, Euromoney, and Institutional Investor, for five years and his global team ranked first in the inaugural global Institutional Investor poll. Prior to joining Credit Suisse in 1995, Mr. Fletcher was a strategy consultant for 14 years, focusing on the steel, metal transformation, and engineering industries for corporate clients worldwide. He was a founding partner of Beddows & Company, a consulting firm that is now part of the Hatch Consulting Group. He started his career as a lawyer in a London law firm.

Mr. Fletcher earned his BA in English literature from Oxford University.

Member of the Board

Pierre Legault joined the Iroko Pharmaceuticals Board of Directors in April 2015. He is the current Chairman of Poxel Pharmaceuticals and he is also a member of the Board of Directors at Tobira Therapeutics.

Previously, Mr. Legault was Chief Executive Officer of NephroGenex, Inc., Chief Executive Officer of Prosidion, Ltd., and Executive Vice President, Chief Financial Officer, and Treasurer of OSI Pharmaceuticals. Mr. Legault has extensive pharmacy operations experience, having served as President of Eckerd and also as Executive Vice President and Chief Administrative Officer of Rite Aid Corporation. Mr. Legault began his career in the pharmaceuticals industry with Sanofi and legacy companies (Aventis, HMR, MMD), where he held several senior positions including Chief Financial Officer, President of Worldwide Dermatology, and others. Previously, Mr. Legault served on the Boards of Directors of Forest Laboratories, Inc., NPS Pharmaceuticals, Regado Biosciences Inc., Cyclacel Pharmaceuticals, Inc., The Jean Coutu Group (PJC) Inc., and several others.

Mr. Legault received an MBA from McGill University and a BAA from HEC Montreal. In addition, he completed Harvard Business School’s Executive Master’s Program, holds a Six Sigma Green Belt, and is a certified public accountant.

Member of the Board

David C. U’Prichard, PhD, joined the Board of Directors of Iroko Pharmaceuticals in August 2010. He currently serves as President of Druid Consulting, LLC, a Partner at Druid BioVentures LLP, and as advisory board chair of BioMotiv LLC and member of the Board of Managers of the accelerator companies BioMotiv LLC and Arix Bioscience Ltd. He is Chairman of the Board of Cyclacel Pharmaceuticals, Inc. and a member of several other biotech company boards.

Dr. U’Prichard has served as Chairman of the Pennsylvania Biotechnology Association, and since 2003 on the Boards of Life Technologies Corp. and multiple other biotech companies, and the professional organizations BioAdvance, Ben Franklin Technology Partners of Southeastern Pennsylvania, and the Bioethics Institute of the University of Pennsylvania. In addition, he has served as a Venture Partner at Red Abbey Venture Partners, Apax Partners Ltd., and Care Capital, LLP.

Prior to 2003, Dr. U’Prichard held a variety of positions within the biopharma industry including: CEO of 3-Dimensional Pharmaceuticals, Inc., Chairman of Research and Development at SmithKline Beecham, and Executive Vice President and International Research Director at ICI/Zeneca. While at ICI/Zeneca and SmithKline Beecham, Dr. U’Prichard oversaw the discovery and development of a number of successful drugs including Seroquel®, Accolate®, Avandia®, and Iressa®. Prior to ICI/Zeneca, he was instrumental in the launch of Nova Pharmaceuticals. Before joining the pharmaceutical industry, Dr. U’Prichard was a tenured Associate Professor of pharmacology and neurobiology at Northwestern University Medical School, following his postdoctoral fellowship at Johns Hopkins University.

Dr. U’Prichard received his PhD in pharmacology from the University of Kansas and his BS in pharmacology with first-class honors from the University of Glasgow, Scotland. He is an Honorary Professor at the University of Glasgow and an author of more than 100 primary and review publications, was a founding co-editor of Molecular Neurobiology, co-editor of Epinephrine in the Central Nervous System, and has served as a member of various editorial boards. He is a Trustee of the International House of Philadelphia and The Wilma Theater.

Seroquel®, Accolate®, and Iressa® are registered trademarks of AstraZeneca. Avandia® is a registered trademark of GlaxoSmithKline.

Management Team

Louis J. Vollmer

President and Chief Executive Officer

Louis J. Vollmer is an experienced pharmaceutical industry executive, with expertise in both chemistry and business. Mr. Vollmer was a co‐founder of the generics business at DuPont Pharmaceutical and was one of the partners responsible for the subsequent $300MM management buy‐out of that and other related businesses, which eventually became Endo Pharmaceuticals Inc. Endo has grown to become a multi‐billion dollar publicly traded company.

As the Founding Executive Vice President of Sales and Marketing for Endo Pharmaceuticals Inc., Mr. Vollmer led the effort to build and deploy a Contract Sales Force. In this regard, Mr. Vollmer was intricately involved in the negotiations and structuring of the CSO contract that enabled Endo’s many successful product launches. Endo did not switch over the CSO to become Endo employees for over five years after the start of the company.

In addition, Mr. Vollmer provided leadership in developing and implementing the strategies required to market Endo’s re‐protected and re‐positioned multi‐source and generic products into the marketplace. These efforts included: launching a re‐positioned Percocet® that offered more convenient doses for patients than the available generic combination oxycodone/acetaminophen products, launching a re‐protected generic hydrocodone as the brand Zydone®, and launching a re‐protected generic lidocaine as the branded product Lidoderm®. Lidoderm® eventually had annual sales of over $1BB and propelled Endo to become a multi‐billion dollar company.

Prior to starting Endo, Mr. Vollmer was employed by DuPont Merck for 19 years, holding several positions ranging from Sales Rep to Senior Marketing Research Analyst to District Sales Manager to Vice President of Sales & Marketing for DuPont Multi‐Source Products, a position with responsibility for over 12 branded products.

Among his achievements beyond the significant amount of revenue that he generated for DuPont Merck and Endo, Mr. Vollmer has also received a number of corporate awards, including being inducted in 1991 into the DuPont Marketing Research Hall of Fame.

Mr. Vollmer earned a Bachelor of Arts degree in biology and chemistry from the University of Delaware in 1978.

Percocet®, Zydone®, and Lidoderm® are registered trademarks of Endo Pharmaceuticals

Vice President, Quality

Gary P. Budney has more than 36 years of pharmaceutical manufacturing, technical services, quality operations experience that includes branded and generic prescription, as well as over the counter product lines. At Iroko, he has overall responsibility for quality operations.

Prior to joining Iroko, Mr. Budney held senior leadership roles in quality operations for CorePharma, Warner-Chilcott, and Danbury Pharmacal/Watson Pharmaceuticals. Also in the role of Compliance Officer, he supported the Manufacturing, Quality, and R&D organizations at Schering-Plough. During the course of his career, he has built and developed quality organizations and the associated quality systems to achieve cGMP compliance, as well as key business objectives that include product launches and transfers, manufacturing plant start-ups and renovations, and quality system remediation to address cGMP compliance deficiencies.

Mr. Budney earned a Bachelor of Science degree in pharmacy from Duquesne University.

Senior Vice President, Sales

Clarissa Etter-Smith has over 20 years of commercial pharmaceutical experience in sales, key accounts, and commercial operations. She has worked in a number of therapeutic areas including oncology, neuroscience, respiratory, GI, and cardiovascular. At Iroko, she has overall responsibility for sales, commercial sales operations, sales training, and sales analytics.

Prior to joining Iroko in 2015, Ms. Etter-Smith held senior leadership roles in sales, commercial operations, leadership development, and sales training at Biogen, Shire, and AstraZeneca. During the course of her career she has launched new products, developed strategies to improve sales teams’ performance and effectiveness, and built a comprehensive leadership development program to improve leadership capabilities. Most recently, Ms. Etter-Smith was the Senior Director of Commercial Operations at Biogen, where she led the US Commercial Operations team. As a member of the US Commercial Leadership Team, she led the training, nursing, and key opinion leader effort for both the hemophilia and multiple sclerosis franchises. Her teams were also responsible for all strategic analytical and operations support for the US business.

Ms. Etter-Smith earned a Bachelor of Arts degree in communications with an emphasis in business from the University of Kentucky.

Senior Vice President, Commercial Operations, Europe and International

Humphrey Harte is a senior executive with 29 years’ experience in the pharmaceutical industry, having operated at a global, regional, and country level. Mr. Harte is responsible for leading all commercial activities for Iroko across Europe, Latin America, Southeast Asia, Africa and the Middle East, Australasia, China, and the Indian sub-continent. He is a strategic thinker with the ability to translate complex messages clearly and with significant cultural awareness. Using these skills, Mr. Harte sources partners and distributors who will effectively commercialize Iroko’s products. Mr. Harte is the external face of Iroko and acts as the facilitator between the partner and the Iroko functions to ensure Iroko effectively supports and educates the partner so they maximize the potential within the relevant markets for Iroko’s assets.

Mr. Harte has progressed through a number of marketing, commercial, and senior executive positions within venture capital-backed start-ups as well as small and large pharmaceutical companies. Prior to joining Iroko in 2007, Mr. Harte was Vice President, Commercial Operations, Europe, and General Manager UK at Novartis Vaccines. Previously, he was a member of the Senior Commercial Executive team at Chiron Vaccines (now part of Novartis) and created PowderJect Pharmaceuticals’ (which was acquired by Chiron) first European Sales and Marketing team. During his 10 years at SmithKline Beecham, he held several positions of increasing responsibility in sales, training, marketing, and leadership roles. Mr. Harte was a key member of a number of product launch teams as well as the creation of the SB Vaccines division.

Mr. Harte earned a BSc (cum laude) in pharmacology from Liverpool University, is a member of the UK Institute of Directors, and was Vice-Chairman of the UK Vaccines Industry Group.

Senior Vice President, Strategic Planning and Business Support

Paul Hemsley joined Iroko in 2007 and has more than 25 years of experience in pharmaceutical companies and consulting firms. His responsibilities at Iroko include supporting the overall strategy of the company, coordinating the strategic planning process, setting corporate objectives, and, through the project management function, ensuring effective planning and implementation of critical activities. He is also responsible for the business analytics and corporate communications areas.

Previously, Dr. Hemsley was Vice President, Global Strategic Planning, and Vice President, Marketing, at Novartis (formerly Chiron) Vaccines. Earlier, as a management consultant, he advised life-sciences companies on commercial and R&D strategy and worked at Glaxo Wellcome (Burroughs Wellcome) as a clinical research scientist, a global brand manager, and a corporate strategy advisor.

Dr. Hemsley earned his BSc in physiology and PhD in neurobiology from the University of London and an MBA from The Open University Business School, UK.

Senior Vice President, Pharmacovigilance, Medical Affairs and Information

E. Olaolu Imasogie has more than 28 years of experience in medicine, information technology, and the pharmaceutical industry. At GlaxoSmithKline, he designed Continuing Medical Education programs for the metabolic therapeutic area and worked in Medical Information and Medical Affairs. Earlier, he served as the chief executive officer of a consulting firm that counseled governmental and private medical institutions in incorporating information technology into the delivery of medical services. At Iroko, he has overall responsibility for medical affairs, medical information, and pharmacovigilance for all Iroko drug products.

Olaolu has practiced medicine in the specialties of internal medicine and obstetrics and gynecology. During his diverse professional experience, he has worked in the US, the UK, and Canada.

He earned his BSc. (Chemistry) and MD degree from the University of Ibadan, Nigeria. He is a certified Microsoft Systems Engineer and is certified by the Council for Continuing Pharmaceutical Education.

Senior Vice President and General Counsel

Moji James has more than 20 years of experience as an attorney, during which time she has supported the development and launch of high-profile drugs, biologics, and vaccines. At Iroko, she has overall responsibility for its legal and compliance functions. Prior to her appointment at Iroko, she was Global Product Counsel at Pfizer and before that was Senior Attorney at Wyeth Pharmaceuticals (now part of Pfizer). During her combined Wyeth-Pfizer tenure, she served as the primary business lawyer for several therapeutic areas, including transplant, neuroscience, and US vaccines. She also worked on Pfizer’s rare disease franchise. Before joining Wyeth, she was a litigator with Shearman & Sterling in New York and later joined Blank Rome as a senior litigator, focusing her practice on complex litigation matters.

Ms. James has a Bachelor of Laws degree from Warwick University, England, and a Master of Laws from London University. Ms. James is a Board member of the Mental Health Association of Southeastern Pennsylvania and serves on its Governance committee and is also a member of The Forum of Executive Women.

Vice President, Regulatory Affairs

Paul M. Kirsch has more than 33 years of pharmaceutical industry experience, 23 of which are in Regulatory Affairs, with the balance of time in Clinical Research. He started at Iroko Pharmaceuticals as Executive Director, Regulatory Affairs in July of 2013 and was promoted to his current role as Vice President, Regulatory Affairs in July 2014. He is responsible for the worldwide regulatory activities for all products.

Prior to joining Iroko, Mr. Kirsch spent over 18 years at Cephalon, Inc. (now Teva Branded Products), most recently as Senior Director and Team Lead in Regulatory Affairs for the CNS Therapeutic area, specifically in excessive sleepiness, psychiatric disorders, pain, and epilepsy. He was also responsible for the International regulatory activities for all global products in Asia-Pacific, Canada, Mexico, and South America. Prior to his tenure at Cephalon, Mr. Kirsch worked at Wyeth (Wyeth-Ayerst) for 10 years in both Clinical Research and Regulatory Affairs.

Mr. Kirsch earned a BS in biology from the University of Scranton.

Senior Vice President and Chief Financial Officer

Fred C. Krieger has more than 30 years of experience managing a wide array of financial functions at international pharmaceutical companies. He has oversight responsibilities at Iroko for the accounting, financial planning and analysis, financial reporting, and tax and treasury functions.

Previously, Mr. Krieger served as Vice President, Financial Control, Planning and Reporting, at GlaxoSmithKline Pharmaceuticals Research & Development. There he directed the R&D accounting, consolidation, and reporting process, and was responsible for the overall budgeting and 3-year planning process for R&D. Mr. Krieger formerly held positions of increasing responsibility at SmithKline Beecham Pharmaceuticals, including positions in Philadelphia and London. For a number of years, he directly supported the chief executive officer.

Mr. Krieger holds BBA and MBA degrees from the Fox School of Business at Temple University and currently serves on the Dean’s Advisory Council. He is a certified public accountant.

Senior Vice President, Corporate Development & Alliance Management

Rohit C. Mehta has nearly 25 years of experience across a broad range of business development activities including licensing, product acquisitions, M&A, due diligence, joint ventures, technology assessment, supply chain, and operations. At Iroko, he leads all corporate and business development activities and is responsible for alliance management and has successfully established a global network of a secure and efficient supply chain consisting of eight manufacturers and seven suppliers across four continents. In addition, Mr. Mehta provides strategic guidance and leadership in all trade relations activities.

Prior to joining Iroko, Mr. Mehta was a principal at Jay Consulting, a firm providing business and corporate development advice to venture capital firms, drug delivery, biotechnology, and pharmaceutical companies in the United States and Asia. Previously, he served as Vice President, Corporate Development, at Dr. Reddy’s Laboratories (US) and at EpiCept Corporation (now Immune Pharmaceuticals), and as Director, Business Development, at Endo Pharmaceuticals.

Mr. Mehta earned an MBA in international business from Temple University, a Master’s in plastic engineering from the University of Massachusetts at Lowell, and a BSc in chemistry (major) and physics and mathematics (minors) from Bombay University, India. He is a member of the Board of the Center for Frontier Sciences at Temple University and the Business Advisory Board of Pharm Asia News, an Informa publication.